Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Biomarin Pharmaceuticals 770 Lindaro Street San Rafael CA 94901 USA

www.bmrn.com P: 415-506-6700 F: 415-382-7889

Description:

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

Key Statistics

Overview:

Market Capitalization, $K 15,653,708
Enterprise Value, $K 15,392,458
Shares Outstanding, K 189,880
Annual Sales, $ 2,419 M
Annual Net Income, $ 167,650 K
Last Quarter Sales, $ 648,830 K
Last Quarter Net Income, $ 88,660 K
EBIT, $ 145,290 K
EBITDA, $ 253,260 K
60-Month Beta 0.34
% of Insider Shareholders 1.85%
% of Institutional Shareholders 98.71%
Float, K 186,367
% Float 98.15%
Short Volume Ratio 0.28

Growth:

1-Year Return -15.04%
3-Year Return 6.72%
5-Year Return -7.45%
5-Year Revenue Growth 62.23%
5-Year Earnings Growth 472.73%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.71 on 04/24/24
Latest Earnings Date N/A
Earnings Per Share ttm 1.35
EPS Growth vs. Prev Qtr 88.46%
EPS Growth vs. Prev Year 25.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

BMRN Ratios

Ratio
Price/Earnings ttm 62.07
Price/Earnings forward 42.36
Price/Earnings to Growth 1.32
Return-on-Equity % 5.34%
Return-on-Assets % 3.89%
Profit Margin % 6.93%
Debt/Equity 0.10
Price/Sales 6.58
Price/Cash Flow 46.84
Price/Book 3.14
Book Value/Share 26.29
Interest Coverage 11.87
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar